CSF1R and B-cell chronic lymphocytic leukemia: CLL primary patient samples were exposed to each CSF1R inhibitor alone and to combinations of each inhibitor with ibrutinib or idelalisib in equimolar concentrations, and combination index (CI) values were calculated (Figure 5A) [31].